HomeAI · summaries
Storia in 3 fonti
GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win
In what GSK says represents a potential way to transform treatment for patients with certain types of rectal cancer, the company’s Jemperli has met the main goal of a phase 2 trial, teeing up an ap | In what GSK says represents a potential way to transform treatment for patients with certain types of rectal cancer, the company’s Jemperli has met the main goal of a phase 2 trial, teeing up an application with the FDA.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
GSK's Jemperli meets main goal in mid-stage rectal cancer trial
GSK's cancer drug Jemperli met a key goal in a mid-stage trial. This drug targets a specific rectal cancer subtype affecting a small percentage of patients. Current treatments for…
- ·
benzinga.com
What's Going on With GSK Stock Monday? - GSK (NYSE:GSK)
GSK Jemperli shows sustained complete responses in dMMR/MSI-H rectal cancer, potentially eliminating the need for surgery or chemo.
